Condition: Diabetic Macular Edema · Diabetic Retinopathy · Sponsor: Therini Bio Pty Ltd
THN391-OPT-101 is a study assessing safety and preliminary efficacy of THN391 in patients with diabetic macular edema (DME) given as monotherapy.
This description comes directly from the study's public registry record.
Liza Wallace · +1 (925) 819-1952 · lwallace@therinibio.com
Joel Naor · +1 (510) 364-2776 · jnaor@therinibio.com
Always discuss trial participation with your own doctor first.
| Marsden Eye Specialists | Parramatta, New South Wales, Australia | Recruiting |
| South Eastern Sydney Local Health District | Sydney, New South Wales, Australia | Recruiting |
| Sydney West Retina | Westmead, New South Wales, Australia | Recruiting |
| Princess Alexandria Hospital | Woolloongabba, Queensland, Australia | Recruiting |
| Royal Adelaide Hospital | Adelaide, South Australia, Australia | Recruiting |
| Sunshine Eye Surgeons | Albans, Victoria, Australia | Recruiting |
| Eye Surgery Associates Pty Ltd | Malvern, Victoria, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06701721